Stockscreener 앱 받기
62.53
1.63%
1.00
시간 외 거래:
62.53
전일 마감가:
$61.53
열려 있는:
$61.7
하루 거래량:
2.19M
Relative Volume:
1.50
시가총액:
$12.70B
수익:
$2.75B
순이익/손실:
$322.29M
주가수익비율:
37.44
EPS:
1.67
순현금흐름:
$300.88M
1주 성능:
-2.01%
1개월 성능:
-4.77%
6개월 성능:
-25.64%
1년 성능:
-32.22%
1일 변동 폭
$61.56
$63.03
1주일 범위
$60.63
$64.72
52주 변동 폭
$60.63
$94.85
바이오마린 Stock (BMRN) Company Profile
명칭
Biomarin Pharmaceutical Inc
전화
(415) 506-6700
주소
105 DIGITAL DRIVE, NOVATO, CA
BMRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
62.53 | 12.70B | 2.75B | 322.29M | 300.88M | 1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
바이오마린 Stock (BMRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-30 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-20 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | 개시 | Evercore ISI | Outperform |
| 2023-11-15 | 개시 | Wells Fargo | Overweight |
| 2023-10-23 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | 개시 | Raymond James | Mkt Perform |
| 2023-09-18 | 개시 | UBS | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-07-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2023-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-02-21 | 개시 | Citigroup | Neutral |
| 2023-01-30 | 개시 | BMO Capital Markets | Market Perform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2022-10-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2022-04-25 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | 재개 | Jefferies | Buy |
| 2021-09-09 | 업그레이드 | Stifel | Hold → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-04 | 재개 | Guggenheim | Buy |
| 2021-03-01 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-08-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-08-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | 재확인 | Citigroup | Buy |
| 2020-01-28 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-27 | 개시 | BMO Capital Markets | Market Perform |
| 2020-01-24 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-04-09 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-07 | 재확인 | Stifel | Buy |
| 2018-08-03 | 재확인 | Stifel | Buy |
모두보기
바이오마린 주식(BMRN)의 최신 뉴스
Sabry Lays Out BioMarin’s New Business Development Plan - News & Insights
Earnings are growing at BioMarin Pharmaceutical (NASDAQ:BMRN) but shareholders still don't like its prospects - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN) Stock: The Under-the-Radar Stock Poised for Massive Upside in 2025 - Insider Monkey
10 Under-the-Radar Stocks with Massive Upside for 2025 - Insider Monkey
Avanza Fonder AB Takes Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Sees Large Decrease in Short Interest - MarketBeat
Moderna, GameStop And Snap Are Among Top Large-Cap Losers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? - Benzinga
BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price Down 3%Should You Sell? - MarketBeat
BioMarin Pharmaceutical Target of Unusually High Options Trading (NASDAQ:BMRN) - MarketBeat
BioMarin stock touches 52-week low at $60.77 amid challenges - MSN
BioMarin Pharmaceutical (NASDAQ:BMRN) Reaches New 52-Week LowWhat's Next? - MarketBeat
BioMarin files UPC’s first pharma infringement suit in over three months - IAM
Are BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? - Simply Wall St
Assenagon Asset Management S.A. Grows Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Wedmont Private Capital Makes New $430,000 Investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Shares Down 3%What's Next? - MarketBeat
UTHR: 3 Niche Biotech Stocks Redefining Innovation - StockNews.com
Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines - Yahoo Finance
5 Biotech Stocks Worth Adding to Your Portfolio in 2025 - Yahoo Finance
Goldman Sachs maintains Buy on BioMarin shares - Investing.com
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives $94.20 Consensus Target Price from Analysts - MarketBeat
BioMarin sues Ascendis Pharma over patent infringement By Investing.com - Investing.com Canada
BioMarin sues Ascendis Pharma over patent infringement - Investing.com
BioMarin Takes Legal Action Against Ascendis Over CNP Patent in European Court - StockTitan
Wall Street Analysts Predict a 45.86% Upside in BioMarin (BMRN): Here's What You Should Know - Yahoo Finance
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - Yahoo Finance
Zacks Research Has Optimistic Outlook of BMRN Q2 Earnings - MarketBeat
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - MSN
Zacks Research Analysts Lift Earnings Estimates for BMRN - MarketBeat
Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators - Benzinga
BioMarin Pharmaceutical (NASDAQ:BMRN) Trading 2.4% HigherStill a Buy? - MarketBeat
XBI, NBIX, GILD, BMRN: Large Outflows Detected at ETF - Nasdaq
Zacks.com featured highlights include Leidos, Amazon.com, Halozyme Therapeutics and BioMarin Pharmaceutical - Yahoo Finance
BMRNBioMarin Pharmaceuticals Inc Latest Stock News & Market Updates - StockTitan
BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA - PR Newswire
BioMarin CEO to Present at J.P. Morgan Healthcare Conference 2024 - StockTitan
BioMarin plans €60m expansion at Shanbally site - The Southern Star
Layoff Tracker: Regeneron Acquisition of Oxular Wipes Out Oxular Workforce - BioSpace
3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN) - Yahoo Finance
BMRN or TECH: Which Is the Better Value Stock Right Now? - Yahoo Finance
Global Mucopolysaccharidosis Treatment Market to Witness Robust Growth, Projected to Reach USD 5,014.5 Million by 2035 Growing at a CAGR of 5.9% | FMI - GlobeNewswire Inc.
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - MSN
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Short Interest Down 9.4% in December - MarketBeat
Sangamo Shares Nosedive as Pfizer Drops Hemophilia Drug Pact - Wall Street Pit
Does BioMarin Pharmaceutical (NASDAQ:BMRN) Have A Healthy Balance Sheet? - Simply Wall St
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term - Yahoo Finance
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Position Trimmed by Principal Financial Group Inc. - MarketBeat
First Week of February 2025 Options Trading For BioMarin Pharmaceutical (BMRN) - Nasdaq
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical (BMRN) Stock? - MSN
Stifel Financial Corp Decreases Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives $94.20 Average Price Target from Brokerages - MarketBeat
바이오마린 (BMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):